Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Biotechs Race To Get First Global IO Green Light Within Months

Multiple US Fast-Track Reviews Underway

Executive Summary

Within months, one of the three latest immuno-oncology drugs from Chinese firms Innovent, Junshi and Akeso is likely to be approved, providing new competition to global giants such as BMS and Merck & Co. as they race each other over to the finish line.

You may also be interested in...



China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World

The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.

China Offers Level Field In Trade Pact Bid But Multiple Pharma Barriers Remain

China has signaled that it will offer a more level playing field to foreign players as part of a bid to join a major regional trade pact but some see the gesture as offering little real relief and high hurdles remain.

China Hits Two Billion COVID Jabs But More Effective mRNA Shots Elude

Despite administering a total of 2.2 billion COVID-19 shots, China as the first country to experience the coronavirus outbreak has yet to open its borders, while more effective mRNA vaccines are still nowhere to be found amid apparent delays for the licensed-in lead candidate.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel